Market Watch

01 Jun 2026, 12:06 UTC · 2h ago

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

Read original · https://www.marketwatch.com/story/an-experimental-lung-cancer-drug-could-replace-keytruda-one-day-but-investors-arent-wowed-873c5f1f

Search tags

Story key points

1 claims · impact-rated

What matters in this story

1
The study found that ivonescimab reduced the risk of death by 34% compared with another drug. — Strong clinical efficacy data regarding survival rates typically leads to significant stock price appreciation for the developer and potential market share gains.
+0.80

Ticker attribution

Model heads

Sentiment in this article

No ticker sentiment head found.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

Browse live screenings

Impact vectors

7 dimensions · 9 clusters

Analytical profile by cluster

6 related stories

PRNewsWire
14h ago
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
- biotech
- clinical trial
- oncology
Read

An experimental lung-cancer drug could replace Keytruda one day. But… · News Impact Screener

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

Top impact dimensions

Most positively impacted

Most negatively impacted

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

Legend Biotech Conference Spotlights CARVYKTI's Curative Potential, Earlier Use

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Next reads from the same story arc

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Next reads from the same story arc

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

Top impact dimensions

Most positively impacted

Most negatively impacted

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

Legend Biotech Conference Spotlights CARVYKTI's Curative Potential, Earlier Use

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026